Ezetimibe Inhibits Triple-Negative Breast Cancer Proliferation and Promotes Cell Cycle Arrest by Targeting the PDGFR/AKT Pathway

Investigators demonstrated that Ezetimibe inhibited the PDGFR/AKT pathway, thereby halting TNBC cycle progression and tumor growth.